Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Newegg Commerce Inc (NEGG) Price & Performance

Amylx Pharmaceuticals IncTrade
Newegg Commerce IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Newegg Commerce Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.59 (market cap $2.64B), while Newegg Commerce Inc trades at $19.08 (market cap $398.29M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 6.6× Newegg Commerce Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.

AMLXNEGG
Market Cap
$2.64B$398.29M
Sector
HealthConsumer Cyclical
52-Week High
$24.19$128.09
52-Week Low
$7.82$12.87
Enterprise Value
$2.39B$397.09M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

Newegg Commerce Inc

NEGG trades at $18.99, up 3.32% today, with a bullish technical signal from moving averages. Recent earnings beat expectations, showing improved profitability with a net income margin of 0.39% in 2025, up from negative margins in prior years. The company maintains a low P/S ratio of 0.28, but a high P/E of 73.16 reflects growth expectations. News highlights include AI shopping features and product launches, indicating innovation efforts.

Outlook: NEGG shows operational improvement with narrowing losses, but negative operating cash flow and high valuation multiples pose risks. The sole analyst coverage is bullish, yet investor caution is warranted due to competitive pressures and reliance on tech spending cycles. Upside depends on sustained revenue growth and margin expansion.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Newegg Commerce Inc

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.

Read more on NEGG